**ESMO 2026** is the annual congress of the European Society for Medical Oncology, held this year in Madrid — the field's marquee stage where late-breaking trial results can reshape treatment standards and move markets overnight. For investors, clinicians, and biotech watchers, it's the calendar event where oncology's biggest questions get answers. This year's headlines delivered drama. The most anticipated readout — Merck and Moderna's personalized mRNA melanoma vaccine, intismeran autogene — hit the hall early after an embargo violation, revealing a 42% reduction in recurrence risk in a large trial. Yet Moderna shares still sold off. Tango Therapeutics stole the pancreatic cancer spotlight: its vopimetostat paired with Revolution Medicines' Rasonque produced an 82% tumor response rate, with 88% of patients alive and progression-free at nine months — chemo-free firepower in oncology's toughest indication. Amgen's Imdelltra and AstraZeneca's Imfinzi also posted notable small cell lung cancer combination data. The takeaway: ESMO 2026 validated two converging theses — mRNA cancer vaccines inching toward commercial reality, and targeted combinations displacing chemotherapy. Watch for regulatory filings, follow-up survival data, and partnership activity cascading from these presentations in the months ahead.